Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
5 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Veru Inc.’s names, not what it holds today.
Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 1 in 2023
Applications published
21
3 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
VERU INC. its own name
US, as the owner printed on each patent
11 publishedASPEN PARK PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
7 publishedVERU INC. its own name
named as the applicant on its applications, in US
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 4, 2025 | 12,240,834 | Polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4- yl] (3,4,5-trimethoxyphenyl)methanone and its salts | Pharmaceuticals | VERU INC. |
| May 16, 2023 | 11,648,236 | Methods of treating coronavirus | Pharmaceuticals | VERU INC. |
| Sep 1, 2020 | 10,758,500 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | Pharmaceuticals | ASPEN PARK PHARMACEUTICALS, INC. |
| Nov 5, 2019 | 10,463,635 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | Pharmaceuticals | ASPEN PARK PHARMACEUTICALS, INC. |
| Mar 13, 2018 | 9,913,815 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | Pharmaceuticals | ASPEN PARK PHARMACEUTICALS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 17, 2025 | 2025/0228804 | USES OF SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) COMPOUNDS FOR QUALITY WEIGHT LOSS | Pharmaceuticals | VERU INC. |
| Jun 5, 2025 | 2025/0179048 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXYPHENYL)METHANONE AND ITS SALTS | Pharmaceuticals | VERU INC. |
| May 29, 2025 | 2025/0170091 | USES OF SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) COMPOUNDS IN CHRONIC WEIGHT MANAGEMENT | Pharmaceuticals | VERU INC. |
| Jun 6, 2024 | 2024/0180879 | METHODS OF TREATING INFLAMMATION | Pharmaceuticals | VERU INC. |
| Nov 2, 2023 | 2023/0348433 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXY)METHANONE AND ITS SALTS | Pharmaceuticals | VERU INC. · patent 12,240,834 granted from it |
| Oct 12, 2023 | 2023/0321045 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | Pharmaceuticals | VERU INC. |
| Aug 24, 2023 | 2023/0265081 | METHODS OF TREATING CORONAVIRUS | Pharmaceuticals | VERU INC. |
| Jun 8, 2023 | 2023/0172897 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | Pharmaceuticals | VERU INC. |
| Aug 18, 2022 | 2022/0257552 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | Pharmaceuticals | VERU INC. |
| Oct 7, 2021 | 2021/0308105 | METHODS OF TREATING CORONAVIRUS | Pharmaceuticals | VERU INC. · patent 11,648,236 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.